During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
References
The Department for Environment, Food and Rural Affairs (Defra) has today released details of the strategy for rolling out vaccination across England.
Under EU law, vaccination can only be carried out in a Protection Zone. As vaccine starts to be delivered by Intervet, vaccination will, therefore, commence in the Protection Zone only. Once vaccination is progressing across the Protection Zone, the intention is to extend or modify the Zone county by county, in order to permit further vaccination. The strategy has been developed and agreed with a Core Group of industry stakeholders. It is designed to be flexible, taking into account the changing nature of the disease, such as moving zones, the varying levels of disease risk in the zones and the availability of vaccine.
More details of the vaccination strategy, alongside indicative prices for the vaccine, can be found on the Defra website: http://www.defra.gov.uk/animalh/diseases/notifiable/bluetongue/control/vaccination-rolloutplan.htm
The recategorisation means that pharmacists and Suitably Qualified Persons (SQPs) will be able to prescribe Zolvix.
The VMD says that making the anthelmintic more widely available will increase its usage as part of strategic worm control programmes on farms, which could in turn result in long term health benefits for sheep, for example by reducing the development and spread of anthelmintic resistance, thereby prolonging the effective use of anthelmintics.
The VMD adds that SQPs will now have additional training to ensure they are sufficiently familiar with Zolvix and how to prescribe it effectively and responsibly so that it is used appropriately. A new compulsory training module will be implemented by The Animal Medicines Training Regulatory Authority (AMTRA) to augment the skills of all AMTRA-registered SQPs permitted to prescribe farm animal products. New SQPs will be required to undertake a revised and extended module before gaining their farm animal registration with AMTRA.
Pharmacists and SQPs will be able to prescribe Zolvix from 1st July 2017.
UPDATE 16th March:
BVA President Gudrun Ravetz has issued a statement expressing concern over the recategorisation of Zolvix:
"We know that resistance to anthelmintics is increasing in grazing animals and needs to be addressed if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites. The reclassification of Zolvix from POM-V to POM-VPS is in direct opposition to the trend in Europe, where we are seeing increased control over dispensing of anthelmintics in species where resistance is a serious threat to animal welfare and profitable production; we're extremely concerned that we might start seeing resistance develop in group 4 as a result.
"BVA believes that prescribing of anthelmintics requires a level of control best provided by a veterinary surgeon who has the animals under his/her care, and is based on a sound clinical diagnosis, in order to protect animal welfare and safeguard the efficacy of these products for the future."
Further information on BVA's policy on anthelmintics can be found on BVA’s website: www.bva.co.uk/news-campaigns-and-policy/policy/medicines/anthelmintics.
Dechra Veterinary Products has launched Ketodale, an anti-inflammatory injection for cattle, horses and swine.
Ketodale contains the non-steroidal anti-inflammatory drug ketoprofen 100mg/ml. It is indicated for use in cattle and swine for diseases associated with inflammation, pain or fever. In cattle these include respiratory diseases, mastitis, osteoarticular and muscular-skeletal disorders, such as lameness and arthritis, and to ease pain post parturition. Ketodale can be used to treat swine suffering from Mastitis Metritis Agalactia (MMA) Syndrome and respiratory tract infections.
In horses, Ketodale is indicated for diseases affecting the osteoarticular and muscular-skeletal system associated with pain and inflammation. These include naviculitis, arthritis and laminitis. It can also be used for post-surgical inflammation and symptomatic therapy of colic and fever.
Ketodale is available in 50ml and 100ml vials.
To coincide with the product's launch, Dechra is carrying out a direct marketing campaign. Practices can take advantage of a special launch offer where they can purchase four vials and get a fifth free. The offer is available for a limited period only.
To find out more about Ketodale, call Dechra on 01743 441 632 or visiting www.dechra.com
Rubén Del Pozo Sacristán (pictured right), technical manager for pigs at MSD Animal Health UK, will be delivering the seminars.
He said: “At MSD Animal Health UK, we’re committed to helping further the knowledge and expertise of vets, so we have put together a series of seminars which will focus on common and demanding production challenges and diseases facing pig producers.”
The monthly seminars will be suitable for all vets, but especially those who are new to pig medicine.
Each seminar will be worth two to three hours of CPD time, with certificates available for all participants.
Rube added: “Of the 12 seminars we have planned, we’re hoping to hold four of these in a face-to-face capacity, with dinner included for those who attend, to allow for networking and further discussion.
The programme is as follows:
For more information on the academy, or to register your interest, speak to your MSD Animal Health account manager.
Novartis Animal Health UK has announced that it is committed to maintaining a reliable supply of Bovidec BVD virus vaccine throughout the coming season.
The announcement comes following concerns surrounding the availability of BVD vaccines. Novartis Brand Manager Eugene Smyth said: "We have been in discussion with the regulatory authorities to try and ensure we can meet the demand over the coming months and we have a large team of territory managers and technical services veterinarians dedicated to supporting our customers through the season".
Bovidec BVD virus vaccine, immunises adult cattle against the BVD Type 1 virus and for active immunisation of calves against BVD Type II virus.
The BVA Animal Welfare Foundation has announced the availability of an updated version of its A3 poultry poster designed to assist veterinary surgeons identify diseases in free-range birds.
Based on information compiled by Victoria Roberts, Honorary Veterinary Surgeon to The Poultry Club, the BVA says the poster provides an invaluable source of information on diseases affecting exhibition chickens, hens, ducks, geese, turkeys, ornamental waterfowl, quail, ornamental pheasants, guinea fowl and peacocks.
The poster details the symptoms of different diseases, the cause, treatment and species affected as well as sections covering common problems and some causes, common diseases by age and life expectancy for the various bird species. A separate highlighted box contains useful tips for veterinary surgeons to pass on to their clients.
Copies of the poster have been circulated to BVA members as an insert in this week’s Veterinary Record. For further copies (free of charge) please ring 020 7636 6541 and ask for the BVA AWF or email bva-awf@bva.co.uk stating your name and postal address, and quoting AWF Poultry Poster.
The company has identified that inconsistencies in the cleaning process have led to low levels of a previous product being carried over into the Stresnil batch no PP1466, EXPIRY: 30-09-2019.
For more information about the recall, contact Matthew Edwards: elanco_orders@lilly.com or telephone: 01256 779519.
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
Developed by Nottingham Vet School’s Ruminant Population Health Group, the calculator is an online tool that veterinary surgeons and farmers can use 'in the field' to measure and monitor their prescribing and use of antibiotics in dairy cattle. It is available to download free at: https://dairy.ahdb.org.uk/technical-information/animal-health-welfare/amu-calculator/
The development follows a new study by the Nottingham Vet School showing that, in a large sample of dairy farms, 25% of farms used 50% of the total antibiotics used across all farms in a year – with antibiotic footbaths accounting for the biggest volume dispersed into the food chain. The study is published in the Veterinary Record1.
Senior Clinical Training Scholar and veterinary surgeon Robert Hyde said: "We felt it was crucial to provide the means with which to benchmark antimicrobial usage on farms, so that veterinarians and farmers can begin to monitor, and reduce, their levels of antimicrobial usage in a rational manner.
"Our new study provides the first published research into antimicrobial use in British dairy herds as well as factors associated with high usage. We looked at a sample of 358 dairy farms, over a 12-month period, with the total number of cattle being around 81,000 (7% of dairy cows in England). The survey found that most of the antibiotic use was via injections, which accounted for around 78% of the total antibiotics used or sold to the farms."
"What stood out as particularly surprising was the effects of the use of antibiotics in footbaths for conditions like digital dermatitis. Footbaths for cattle can use phenomenal quantities of antimicrobials, and represent an obvious target for the rapid reduction of antimicrobial usage."
Specialist cattle vet and Clinical Assistant Professor John Remnant from Nottingham Vet School said: “We need to be reducing the use of antibiotics on farms to the lowest level we can, but without failing to treat sick animals and reducing welfare standards. This means preventing disease – an area our research group has worked on for many years. Antibiotic use on UK dairy farms has been falling in recent years, as farmers and vets make efforts to turn towards prevention instead of treatment.
"The government has recently published figures showing the sale of antibiotics for food-producing animals has fallen from 62mg per kg of animal to 45mg per kg in the past two years but this is sales, not usage as we know some of the antibiotic products bought won’t be used. This is why our new study combined with the new online AMU tool is so important in helping farmers and vets instigate a more efficient protocol for the treatment of dairy cattle."
Edward Bailey from the George Veterinary Group in Wiltshire is already using the AMU calculator. He said: "This new tool is proving really useful to compare antimicrobial use between farms. It has helped cut through the confusion of different systems of measurement. It has been easier to effect change being able to display graphically to farmers their critically important antimicrobial usage and how particular patterns of use (e.g. footbath) can hugely affect how they compare with others."
Around 50 veterinary practices have already begun using the AMU calculator but the researchers say that antimicrobial benchmarking needs to happen a national level for the system to have maximum impact on antibiotic use in the cattle sector.
Reference
Vetoquinol UK Limited has launched Ceftiocyl: a ready-to-use formulation containing 50mg/ml ceftiofur for use in cattle and pigs.
In cattle, Ceftiocyl can be used for the treatment of respiratory disease, acute interdigital necrobacillosis and acute post-partum metritis. In pigs, Ceftiocyl is licensed for the treatment of respiratory disease. Ceftiocyl has the added benefit of traceability stickers which are attached to each vial making it easier and quicker to record and monitor on-farm usage.
Susan Mitchell, Large Animal Product Manager at Vetoquinol UK Ltd said, 'We are delighted to be expanding our large animal anti infective range offering. Marbocyl 10% has been used for acute mastitis in the dairy sector for many years, the addition of Ceftiocyl to our portfolio enables us to provide a cost-effective treatment for both metritis and lameness.'
1. Willshire, J.A. & Bell, N, J. (2009) An economic review of cattle lameness. Cattle Practice 17, 136-141.
Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
The Westpoint Group has announced the divestiture of its small animal and equine veterinary practices in order to focus on production animal health and welfare.
From now, the production animal business - which includes veterinary practices providing services to pig, poultry, dairy, beef, sheep, game bird producers and small holders - will be known under the umbrella brand of Origin.
The company says that excellence and innovation in client service will continue to be the focus throughout the organisation.
Matt Dobbs, Managing Director of Origin said: "Origin is committed to supporting livestock farmers to enhance production by improving health and welfare. We have a unique group of vets, researchers, lab techs and paraprofessionals passionate about the success of UK agriculture, with other businesses committed to supporting the industry, joining us through the autumn.
"By focusing on supporting farmers, we will become a unique source of animal insight in livestock agriculture."
For more information, visit: http://www.westpointveterinarygroup.com
Norbrook Laboratories Ltd has launched the 2013 - 2014 edition of its UK Veterinary Surgeon's Product Compendium.
The compendium contains data sheets for the complete range of over 120 Norbrook products which are available in the UK and Northern Ireland, including 17 new products which have been launched since the last compendium was issued.
The compendium is available from your Norbrook representative or can be downloaded from www.norbrook.com. Norbrook also offers an iPhone App through which users can access essential product information including pharmaceutical presentation, uses, dosage and administration, withdrawal periods, contraindications & warnings and pharmaceutical precautions.
The current strain of bluetongue emerged in the Netherlands in 2023 and spread rapidly, infecting over 5,000 livestock farms.
Infection of livestock with this serotype of the virus can result in severe clinical signs and high mortality rates1, significantly impacting animal health, and farming communities.
Bultavo 3 is an inactivated injectable vaccine indicated for the active immunisation against BTV-3.
Boehringer says that in sheep, Bultavo 3 has been shown to significantly reduce viraemia and prevent mortality and clinical signs associated with BTV-3 infection.
Onset of immunity occurs three weeks after administration of a single 1ml subcutaneous dose in sheep.
In cattle, two 1ml intramuscular doses are required, at a three-week interval.
Findlay MacBean, Head of Livestock, UK and Ireland at Boehringer Ingelheim, said: “It’s great news that we can support farmers and authorities in their fight against bluetongue with our new BTV-3 vaccine, Bultavo 3.
"As we have seen across Europe, and now in the UK, BTV can spread rapidly and causes considerable stress to farmers because of the significant financial impact on those affected.
The availability of Bultavo 3 means future BTV-3 outbreaks can be suppressed, helping farmers protect not only their herds, but also their livelihoods.” Oli Maxwell, BVSc BSc(Hons) MVM DipECBHM, RCVS Recognised Specialist in Cattle Health and Production and Clinical Director of Green Counties Vets said: “Farmers are justifiably concerned about BTV-3 and its incursion into the UK again this year.
"Reports from colleagues on the continent regarding the severity of clinical signs, especially in sheep are worrying.
"We have seen a huge increase in clients asking about the disease, progress on a vaccine and what this may mean for animal movements at a critical time of year.
"The availability of a safe and effective vaccine as a critical tool against a disease that we can’t reasonably prevent with biosecurity measures will be a welcome development for many.”
To manage supply and demand, use of the product will initially be subject to geographical restriction with vaccination permitted in high-risk English counties: Norfolk, Suffolk, Essex, Kent and East Sussex.
Reference:
The milk withdrawal has been reduced from 108 hours to 96 hours and the dose is now 15 mg/kg for three consecutive days.
Kath Aplin, veterinary adviser for Boehringer Ingelheim Animal Health, said: "The new dosage regimen gives clearer guidance to vets and their clients; a 660kg cow should receive 10g of penethamate hydriodide (one vial) daily for three days.
Mamyzin, a lecithin coated pro-drug of benzyl penicillin, is highly lipophilic and actively concentrates in the udder, where it is capable of entering epithelial cells to achieve intracellular bacterial kill1. It provides targeted, narrow spectrum treatment for gram positive mastitis in situations where injectable therapy for mastitis is required."
In its updated position statement, the association emphasises its support of current UK legislation and says it would like to see improved implementation of current laws, in particular when informed by an evidence-based welfare outcomes approach.
The BVA also recommends that any proposals to improve welfare during transport should embrace all forms of transport and include welfare issues before, during and after movement. This, it says, would help ensure that a well-defined set of animal welfare standards are met for the entirety of any journey.
The BVA recommends that animals are slaughtered as close to the point of production as possible and supports the exploration of further opportunities which would assist this. It recognises that transportation of live animals can be unavoidable in some situations – for example, journeys between the Scottish Islands and Highlands – but says that no animal should be exported to a destination with unknown welfare standards, to one using systems currently banned in the UK or to a country where it would be slaughtered without stunning.
BVA President Simon Doherty said: "Any kind of movement has the potential to impact on an animal’s health and welfare. Ideally, we’d like to see livestock slaughtered close to the point of production, as long as all legislative health and welfare standards can be maintained. However, we recognise the high standards of welfare in the UK and support better implementation of current legislation.
"We have taken care to reiterate that any improvements made to live animal transport should consider welfare issues before, during and after movement so that a more complete approach is taken on this issue.
"We recognise that journey length is not the only influencer of welfare conditions for animals, and transport needs to be looked at as a whole rather than focusing on single factors. The most important thing for Government to do is to consider the evidence base when it weighs up options for making improvements."
Chanelle has announced the launch of Ketamidor 100 mg/ml Solution for Injection (ketamine), licensed for use in cats, dogs, horses, cattle and swine in the UK and Ireland.
The company says the new product provides a versatile addition to anaesthetic regimes. It can be used in combination with other widely-used anaesthetics and sedatives. Chanelle says it also has analgesic properties that make it particularly beneficial to include in anaesthetic protocols when carrying out painful surgical procedures.
Ketamidor 100mg/ml Solution for Injection has a zero day withdrawal period for milk and meat when used in cattle and pigs, allowing high welfare standards to be maintained without compromising economic returns.
According to Chanelle, ketamine is now experiencing a resurgence of interest as its analgesic properties and minimal impact on spontaneous respiration become increasingly appreciated.1
Angela Wilkin, Chanelle UK's Sales and Marketing Manager said: "Ketamidor makes a great addition to our portfolio of pain management products. Our territory managers are looking forward to speaking to those vets who are already accustomed to using ketamine and those that may be considering adding it to their current protocols."
Nominated by a colleague, Will graduated and joined the practice in 2021, having previously worked as a dairy herdsperson.
In his nomination, clients described Will as having an excellent understanding of the practicalities of running a herd, and said he provides realistic and achievable advice.
The judging panel was impressed by Will’s dedication to improving health, welfare, and productivity on dairy farms with his clear advice and workable action plans.
In addition, Will set up an embryo transfer service, bringing a new service to his practice, along with a robot discussion group, all of which have made a significant and positive impact to his dairy farming clients.
Will said: “It was a real privilege to be awarded the Young Dairy Vet of the Year award amongst so many talented and dedicated farm vets in our line of work.
"Above all it is a testimony to the farmers I work with day to day and the proactive attitude they take to improving their systems which has given me so many opportunities to develop my career”.
This year’s runner up was Hana Ward of Torch Vets in Barnstaple, Devon.
Photo: Will with last year's winner, Tom Warboys.
At the start of June, the British Veterinary Association (BVA), British Cattle Veterinary Association (BCVA), Goat Veterinary Society (GVS), and Sheep Veterinary Society (SVS) welcomed the announcement that bluetongue (BTV-8) vaccine would be available by mid-July to support farmers and smallholders in managing the risk of a bluetongue outbreak predicted to reach mainland UK by late summer.
Since the Defra risk assessment indicates a high risk by late summer of a BTV incursion from France, veterinary associations have been involved in discussions with government, farmers’ representatives and manufacturers to ensure vaccine is available to meet potential demand particularly in the south of England where risk is highest. The situation remains under constant review by Defra as the disease develops and the weather warms up, promoting midge activity.
Pharmaceutical companies MSD and Zoetis announced that batches of vaccine would be available from mid-July, which Defra has just confirmed.
Vets across the UK are also contributing to the Joint campaign Against Bluetongue (JAB), helping to make farmers aware of the risk, clinical signs and what action to take, through speaking at local JAB information events and displaying posters and leaflets in practices.
While welcoming the announcement of vaccine availability in June, veterinary organisations also sought clarification about the cost and the amount of vaccine likely to be available in July and thereafter. This information is now available.
BVA President Sean Wensley said: "We welcome the announcement that vaccine will be available in time to meet potential demand. This disease seriously affects animal health and welfare as well as the productivity of livestock, and vaccination is the key control."
Photo by Fourrure (http://www.boulesdefourrure.fr) [CC BY-SA 2.0], via Wikimedia Commons
The President of the British Veterinary Association has written to the Badger Trust to clarify the BVA position on the pilot badger culls in England, stating that it will not be supporting the Trust's application for a judicial review.
The BVA Council agreed a position on the continuation of controlled shooting in the pilot areas on 16 April. The position states that the BVA could only support further culling using controlled shooting in the pilot areas if steps are taken to improve both its effectiveness and humaneness and if there is robust monitoring and collation of results and independent analysis and auditing by a non-governmental body. It also states that the BVA supports the Independent Expert Panel's (IEP) recommendations for improving effectiveness and humaneness and urges Defra to implement all the IEP's recommendations fully.
The BVA says that since 16 April, it has been in dialogue with Defra to seek assurances that these issues will be addressed, and those discussions are ongoing. It will not be taking a further position on the pilot culls until BVA Council has had the opportunity to consider Defra's plans in full, when they are made available.
In a press release dated 20th May, The Badger Trust CEO Dominic Dyer said: "It is not acceptable for the DEFRA Secretary of State to now push aside the concerns of both the Independent Expert Panel and the British Veterinary Association, by moving ahead with a further badger cull in Gloucestershire and Somerset this summer without any independent monitoring in place."
The BVA says it is concerned that this misrepresents its position, and has led to some media reports suggesting that the BVA has withdrawn its support for badger culling as part of the overall strategy to eradicate bovine TB. It has not. The BVA says it continues to believe that the TB eradication strategy for England will only be successful if we are able to use all of the available tools, including targeted, humane badger culling.
Life Technologies Animal Health has announced the launch of a new qPCR test to improve the diagnosis of mastitis and respiratory disease caused by Mycoplasma bovis.
According to the company, the TaqVet Mycoplasma Bovis (M. bovis) polymerase chain reaction (PCR) kit is based on a new target gene in the M. bovis genome and thus can distinguish better between infections caused by M. bovis and M. agalactiae - so there is less risk of false positive results and improved sensitivity and specificity.
The test is based on real-time PCR technology, and delivers results in two and a half hours.
Eric Sellal, Head of Animal Health EMEA at Life Technologies said: "The improved sensitivity of this new test means that veterinarians will be able to monitor dairy herds for sub-clinical infection using samples from the bulk tank. And of course it can also be used to diagnose mycoplasma infection in individual cases of clinical mastitis and respiratory disease."
Life Technologies says the test system incorporates a number of other improvements which simplify and speed up processing in the laboratory, including automatic extraction using magnetic bead technology.
It is estimated that bovine pneumonia costs the European industry around 500million Euros each year, with 30% accounted for by M. bovis. Other diseases associated with the organism include mastitis and arthritis.
Mycoplasma is slow and difficult to culture in the laboratory and current antibiotic treatment is not very cost-effective. Therefore, prevention is a cornerstone of M. bovis management.
The TaqVet Mycoplasma Bovis PCR kit will be made available in other EU countries and via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
Guillaume Fournié and Dr Javier Guitian from the Royal Veterinary College - working with colleagues from the London School of Hygiene and Tropical Medicine and Imperial College - have developed a model to understand how live bird markets act as a "hub" of infection for domestic poultry and if rest days, during which such markets are emptied and disinfected, may reduce transmission.
The results are published today in Interface - the Journal of The Royal Society. PhD student Guillaume Fournié, who led the research, said: "Live bird markets can be a reservoir of infection for domestic poultry and may therefore be responsible for sustaining H5N1 HPAI virus circulation.
"Compared to interventions applied in farms - such as stamping out and vaccination - our model shows that frequent rest days are an effective means with which to reduce H5N1 HPAI infection rates. Furthermore, our model predicts that full market closure - as has been implemented in some countries such as Egypt and Vietnam - would only be slightly more effective than rest days to reduce transmission of the disease."
The models used in the study are based on the live bird market chain in Hong Kong and the analysis restricted to chickens. Fournié, who qualified to be a vet in Alfort in his native France, was awarded fully-funded studentships (tuition fees and a living allowance) in 2007 by The Bloomsbury Colleges - a consortium of six colleges of the University of London: Birkbeck, IoE, LSHTM, RVC, School of Oriental and African Studies, and The School of Pharmacy - to conduct the research.
Since December 2003 outbreaks of H5N1 Highly Pathogenic Avian Influenza (HPA1) affecting domestic poultry have been reported in 50 countries across the world. Massive economic losses and the pandemic threat make H5N1 HPAI one of the greatest current public health concerns.
A full copy of the report can be seen in Interface at http://rsif.royalsocietypublishing.org
Novartis Animal Health has announced that it is offering regular updates Schmallenberg virus, including the number and counties of affected farms, on its farm animal health website: www.farmanimalhealth.co.uk.
The new website is a resource for vets, SQPs and farmers and also contains background information on the virus, its symptoms and suggestions for control.
Helen Langham, Brand Manager at Novartis Animal Health, said: "There is still a lot that isn't known about the Schmallenberg virus, so it is essential that those involved in the animal health industry and livestock production are kept informed. Our website provides current information and links to relevant resources to help people stay up to date".
For more information go to www.farmanimalhealth.co.uk/latestdiseaseupdates